Abstract Library

#4646 Dysregulated miRNA in patients with GEP-NEN and potential role as circulating biomarker

Introduction: Neuroendocrine neoplasms (NENs) are a class of rare and molecularly extremely heterogeneous tumours. NENs arise predominantly in the gastrointestinal (GEP) and pulmonary tracts but can also involve thyroid and breast. NENs often present with non-specific symptoms and lack early specific biomarkers, leading to frequent metastatic diagnoses and primary site challenges.

Conference:

Presenting Author:

Authors: Di Mauro A, Clemente O, Cannella L, Della Vittoria G, Neri G,

Keywords: neuroendocrine tumour, miRNome profiling, biomarker, gep-net, molecular biology,

#4423 Exploring decorin in plasma-derived small extracellular vesicles (sEVs) as a potential diagnostic biomarker for pancreatic neuroendocrine tumours

Introduction: Pancreatic Neuroendocrine tumours (PanNETs), the most common site for GEP‑NENs in Asian countries, particularly India, have shown increasing incidence. Due to a lack of specific biomarkers, often detected at advanced stages. So, this study utilised PanNET tissue proteomics for cancer biomarker discovery and explored the impact of small extracellular cellular vesicles (sEVs) in PanNET growth and metastasis, as they reflect the molecular profile of their tissue of origin.

Conference:

Presenting Author:

Authors: Gorai P, As S, Naik M, Kumar S, Pal S,

Keywords: Decorin, small extracellular vesicles, Pancreatic Neuroendocrine Tumour, Proteomics, circulating biomarker,

#3281 Prediction of progression-free survival in patients with neuroendocrine tumors received 177Lu-Dotatate using circulating biomarkers

Introduction: Few circulating biomarkers are available for prediction of progression-free survival (PFS) in patients with advanced neuroendocrine tumors (NET) received 177Lu-Dotatate.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Chen L, Gnanasegaran G, Mandair D, Toumpanakis C, Caplin M,

Keywords: PRRT, survival, ESR, creatinine, CgA,

#2173 Decreased Serum Amyloid A1 as Potential Diagnostic Marker for Gastro-Entero-Pancreatic Neuroendocrine Neoplasms

Introduction: Gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) are rare tumors with an increased incidence reported in recent years. Researchers have shown that tumor cells produce and secrete more exosomes compared with normal cells. Serum amyloid A1 (SAA1) is elevated in patients with liver cancer, lung cancer, breast cancer, prostate cancer and endometrial cancer. However, the relation between SAA1 and GEP-NENs remains unclear.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Qiyun T

Authors: Na H, Qiyun T,

Keywords: Exosomes, Serum amyloid A1, Circulating biomarkers, Diagnosis,

#1642 Angiogenic Circulating Biomarkers in Patients with Advanced Pancreatic Neuroendocrine Tumors Treated with Everolimus

Introduction: More than 10% of patient treated with Everolimus develop early onset of resistance. The lacking of adequate predictive factors in the targeted hera makes challenging the early identification of non-responders patients.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: cella c

Authors: Cella C, Spada F, Labanca V, Radice D, Rubino M,

Keywords: pancreatic nets, biomarker, everolimus,